Physician profile

Philip Nathan Mayer

Nurse Practitioner · Oklahoma City, OK

NPI 1346550316

$255.06

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$255.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Vanda Pharmaceuticals INC. $67.19 2024 Fanapt
Lundbeck LLC $56.94 2024 Abilify Asimtufii
Teva Pharmaceuticals USA, INC. $49.31 2024 Austedo Xr
Janssen Pharmaceuticals, INC $25.15 2024 Spravato
Takeda Pharmaceuticals U.S.A., INC. $21.27 2024 Trintellix
Alkermes, INC. $19.20 2024 Lybalvi
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $16.00 2024 Caplyta

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Philip Nathan Mayer

$255.06

in general payments reported 2019-2025

Years
2024
Top company
Vanda Pharmaceuticals INC.

https://glasscript.com/doctor/10693851/philip-nathan-mayer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.